Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCCP.OQ)

CYCCP.OQ on NASDAQ Stock Exchange Capital Market

6.25USD
16 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.25
Open
$6.62
Day's High
$6.62
Day's Low
$6.62
Volume
50
Avg. Vol
684
52-wk High
$10.30
52-wk Low
$4.30

CYCCP.OQ

Chart for CYCCP.OQ

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.32
Market Cap(Mil.): $21.32
Shares Outstanding(Mil.): 4.27
Dividend: --
Yield (%): --

Financials

  CYCCP.OQ Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -2.92 -- --
ROI: -71.04 2.29 -5.84
ROE: -73.16 0.06 -5.23

BRIEF-Cyclacel Pharmaceuticals Q1 loss per share $0.38

* Cyclacel pharmaceuticals reports first quarter 2017 financial results

May 11 2017

BRIEF-Intra-Cellular therapies reports Q1 loss per share $0.62

* Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update

May 10 2017

BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program

* Intra-Cellular Therapies provides corporate update on schizophrenia program

May 01 2017

BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140

* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140

Apr 04 2017

BRIEF-Cyclacel Pharmaceuticals reports Q4 and full year 2016 financial results

* Cyclacel Pharmaceuticals reports fourth quarter and full year 2016 financial results

Mar 28 2017

Cyclacel's leukemia drug for elderly patients fails in key study

Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Feb 23 2017

UPDATE 1-Cyclacel's leukemia drug for elderly patients fails in key study

Feb 23 Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Feb 23 2017

Cyclacel's leukemia drug for elderly patients fails in key study

Feb 23 Cyclacel Pharmaceuticals Inc said its experimental drug failed in a late-stage study on patients aged 70 years or more with newly diagnosed acute myeloid leukemia.

Feb 23 2017

BRIEF-Cyclacel reports top-line results from phase 3 study in patients with acute myeloid leukemia

* Cyclacel announces top-line results from pivotal phase 3 seamless study in elderly patients with acute myeloid leukemia

Feb 23 2017

BRIEF-Intra-Cellular Therapies' unit enters into supply agreement with Siegfried Evionnaz

* Intra-Cellular Therapies Inc- on January 4, 2017, co's unit entered into a supply agreement with Siegfried Evionnaz SA- SEC filing Source: (http://bit.ly/2jALlxx) Further company coverage:

Jan 10 2017

More From Around the Web

Earnings vs. Estimates